NASDAQ · Biotechnology

AC Immune SA (ACIU) Stock

$2.50 -1.96% NASDAQ: ACIU Healthcare

Valuation

MetricValue
Price$2.50
Market Cap$254.43M
P/E Ratio-5.24
P/B Ratio6.33
P/S Ratio13.12
EPS (TTM)$-0.70
52-Week High$4.00
52-Week Low$2.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-99.17%
ROA-28.70%
ROCE-88.05%
Gross Margin-1700.00%
Operating Margin-1725.00%
Net Margin-246.49%
Debt/Equity0.12
Current Ratio1.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$4.0M$15.0M$27.0M$4.0M
Operating Profit$-79.0M$-71.0M$-54.0M$-52.0M$-69.0M
Net Profit$-73.0M$-71.0M$-54.0M$-51.0M$-70.0M
EPS$-0.97$-0.85$-0.64$-0.51$-0.70
Op Margin—-1800.4%-362.3%-191.8%-1927.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$261.0M$186.0M$183.0M$231.0M$154.0M
Total Liabilities$29.0M$17.0M$22.0M$119.0M$109.0M
Cash$82.0M$32.0M$78.0M$36.0M$27.0M
Borrowings$3.0M$3.0M$3.0M$5.0M$5.0M

Latest News

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 GlobeNewswire · Jul 7, 2026 AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease MT Newswires · Jun 30, 2026 AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease GlobeNewswire · Jun 30, 2026 ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last? Zacks · Jun 29, 2026 June 2026 Penny Stocks To Watch For Potential Growth Simply Wall St. · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-66.0M$-74.0M$-60.0M$66.0M$-66.0M
Investing Cash Flow$-56.0M$23.0M$65.0M$-106.0M$60.0M
Financing Cash Flow$0$-1.0M$0$-1.0M$0
Net Cash Flow$-79.0M$-51.0M$47.0M$-42.0M$-5.0M
Free Cash Flow$-68.0M$-75.0M$-61.0M$65.0M$-67.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.26
EV / EBITDA-4.91
FCF Yield-15.21%
Quick Ratio0.93
Interest Coverage-263.40
Return 1Y-6.58%
Return 3Y-21.72%
Return 5Y-69.20%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALDXAldeyra Therapeutics, Inc. $0.92 -3.31% -3.02 $55.27M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNXAnnexon, Inc. $4.02 +0.50% -3.61 $658.65M 0.00%
ANROAlto Neuroscience, Inc. $24.37 +1.41% -9.71 $855.24M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%

About AC Immune SA

AC Immune SA is led by CEO Andrea Pfeifer, employs 133 people, headquartered in CH, publicly traded since 2016.

AC Immune SA (ACIU) stock trades at $2.50 with a market capitalization of $254.43M. The stock is valued at a price-to-earnings (P/E) ratio of -5.24, price-to-book of 6.33, price-to-sales of 13.12. Over the past 52 weeks the stock has ranged between $2.10 and $4.00, and currently trades 37.5% below its 52-week high.

On profitability, AC Immune SA generates a return on equity (ROE) of -99.17%, return on capital employed of -88.05%, an operating margin of -1725.00%, a net profit margin of -246.49%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides